Logo-header-sito-copia copia

PRELIMINARY PROGRAMME

GENETICS & EPIDEMIOLOGY

  • Genetics and genomics in celiac disease

  • Triggering disease: the exposome in celiac disease

  • Is it possible to predict celiac disease?

  • Celiac Disease around the world

  • Celiac disease and autoimmunity

  • Viral infections and celiac disease

TRIGGERS AND DRIVERS

  • Wheat proteins, diet, innate immunity and inflammation

  • Gluten as a trigger

  • Bacteria as triggers of celiac disease

  • The role of intestinal microbiota

  • Immune pathways triggered by gliadin

DIAGNOSIS

  • Immune biomakers after gluten exposure

  • Quantitative duodenal histopathology in coeliac disease

  • Not all celiacs are equal

CLINICAL CHALLENGES

  • Mucosal healing: relevant, frequent, assured

  • Mechanistic bases for lack of mucosal healing

  • Potential celiac disease

  • Risk factors for complications in adult coeliac patients

  • Gluten in NCGS: guilt or innocence

NEW TREATMENTS AND PREVENTION

  • Animal models to test new treatments

  • Enzyme therapy

  • Il-15/IL-21 inhibition

  • PRV-015/AMG714: antiIL15 in phase 2 for the treatment of non responsive celiac disease

  • TG2 Inhibition

  • Immune tolerance (nanoparticles and other technologies)

  • Prevention of type 1 diabetes and celiac disease with teplizumab and a coxackievirus vaccine

  • Is prevention only a matter for kids?

  • Possible strategies:

– handling gluten
– protection from infection
– microbial therapeutics for celiac disease
– modulation immune response

DIAGNOSIS

  • Critical issues in the ESPGHAN protocol

  • Celiac disease autoantibodies for diagnosis: which future?

  • Novel insight in coeliac and non-coeliac histology and future aspirations

  • Toward one protocol for children and adults

  • Advanced endoscopy techniques and celiac disease

CLINICAL PRESENTATIONS AND ASSOCIATE CONDITIONS

  • Is clinical presentation in children still changing?

  • Celiac subtypes, moving away from a one size fits all approach

  • Cognitive deficit and white matter changes in celiac disease

  • Coeliac disease and bone health

  • Type 1 diabetes and celiac disease

  • Should IBD patients be screened for celiac disease?

  • IBS and celiac disease

CLINICAL CHALLENGES

  • How to make diagnosis on GFD?

  • What to do in case of negative serology and mucosal damage

  • What to do in case of positive serology and no mucosal damage

  • Celiac disease and metabolic disorders

  • COVID and celiac disease

TRANSLATIONAL ASPECTS OF COELIAC DISEASE

  • Clinical applications of blood gluten specific T cell studies

  • Gluten challenge: immunological changes and clinical applications

  • Autoantibodies against different transglutaminases and their clinical applicability

FOLLOW UP

  • Mucosal healing in adults: an achievable goal?

  • Which protocol for follow-up

  • Probiotics, Prebiotics and Other Dietary Supplements

  • Quality of life in celiac disease

  • Mortality in celiac disease

GLUTEN-FREE DIET AND MANAGEMENT

  • Assessment of compliance

  • Contamination/food labeling

  • Role of dietician

  • Role of patient’s groups

  • Role of Coeliac Centers

PREVENTION & TREATMENT

  • Which lessons from prospective cohorts

  • Refractory coeliac disease

  • Gene editing for wheat detoxification

  • Future treatments: state of the art

  • Future treatments: patient’s expectations

OTHER GLUTEN-RELATED DISORDERS

  • FODMAP as drivers for NCGS/NCWS

  • A biomarker for NCGS